ライフサイエンスコーパス: IVUS

1 IVUS analysis included qualitative and quantitative meas

2 IVUS guidance compared with angiography guidance was ass

3 IVUS guidance has benefits in improving the long-term pr

4 IVUS has been used in clinical trials to evaluate the ef

5 IVUS minimum lumen diameter (MLD), minimum lumen area (M

6 IVUS was associated with an independent and significant

7 IVUS was associated with larger stent diameters (median,

8 IVUS was performed at baseline and study completion.

9 IVUS was utilized in 3349 patients (39%), and larger-dia

10 Baseline 3D IVUS was performed at 0.22 (0.17-1.16) years after trans

11 10 H+LTx recipients in whom two coronary 3D IVUS studies were performed 1 year apart.

12 ars after transplantation, with follow-up 3D IVUS exams performed after baseline exam (0.96 [0.83-1.0

13 Again, IVUS did not disclose this heterogeneity.

14 For amlodipine, IVUS showed evidence of slowing of atherosclerosis progr

15 We conclude that (1) an IVUS MLD and MLA of 2.8 mm and 5.9 mm2, respectively, st

16 Ultrasound signals were obtained using an IVUS system with a 40-MHz catheter and digitized at 1 GH

17 and stent thrombosis might be lower with an IVUS-guided approach.

18 of OCT (AUC: 0.70; 95% CI: 0.55 to 0.83) and IVUS (AUC. 0.63; 95% CI: 0.47 to 0.77; p = 0.19).

19 Standard clinical, angiographic, and IVUS measurements were collected and/or measured.

20 Both CFDI and IVUS depict the blood flow and endoluminal abnormalities

21 The observation that CFDI and IVUS depicted endoluminal abnormalities suggestive of RA

22 CT, or invasive examinations such as DSA and IVUS.

23 nificant inverse correlation between FFR and IVUS-derived measures of plaque burden, including percen

24 ure guidewire was used to calculate FFR, and IVUS parameters were calculated after automatic pullback

25 the feasibility of integrating EIS, ISS, and IVUS for a catheter-based approach to assess mechanicall

26 struts were no longer discernable by OCT and IVUS.

27 VUS) data were acquired from 14 patients and IVUS-based 3D fluid-structure interaction (FSI) coronary

28 The average IVUS area stenosis was markedly greater in RAS with an H

29 Integrated backscatter IVUS has a better potential for characterizing fibrous l

30 Compared with baseline, IVUS showed progression in the placebo group (P<.001), a

31 erformed to examine the relationship between IVUS guidance and 1-year outcomes.

32 r coronary plaque progression as assessed by IVUS, despite an increased prevalence of sensitized pati

33 ssion rate of atherosclerosis as detected by IVUS predicts cardiovascular outcomes is unknown.

34 However, similar defects were detected by IVUS when angiography was borderline (7 patients) or nor

35 Changes in atheroma volume, as determined by IVUS after adjustment for possible confounders by using

36 total of 83 coronary segments were imaged by IVUS (left main, 19; left anterior descending, 51; left

37 coronary arteries were previously imaged by IVUS and 130 arteries were not imaged by IVUS.

38 by IVUS and 130 arteries were not imaged by IVUS.

39 n of coronary atherosclerosis as measured by IVUS.

40 Anatomic measurements by IVUS show a moderate correlation with the FFR values.

41 NS), in-stent percent volume obstruction by IVUS (29% vs. 24%; p = NS), and clinically driven TLR (1

42 Rapidly progressive vasculopathy by IVUS, defined as an increase of >/=0.5 mm in intimal thi

43 patients, MDCT measurements were verified by IVUS.

44 However, comparisons among OCT, C-IVUS, and IB-IVUS have not been done.

45 The sensitivity of C-IVUS was 100%, 93%, and 67%, respectively.

46 The specificity of C-IVUS was 99%, 61%, and 95%, respectively (Cohen's kappa

47 izing fibrous lesions and lipid pools than C-IVUS.

48 and conventional intravascular ultrasound (C-IVUS) for tissue characterization of coronary plaques an

49 tes (42 coronary arteries) from 17 cadavers; IVUS and OCT images were acquired on the same slice as h

50 g coronary angiography is often challenging; IVUS provides useful information for assessment of coron

51 l was constructed based on a 40 MHz clinical IVUS catheter.

52 e, discuss some of the concerns, and compare IVUS results with those of quantitative arteriography.

53 was performed in all cases, with concomitant IVUS imaging in 47 cases.

54 We conducted IVUS studies on 214 patients with angiographically indet

55 After adjusting for potential confounders, IVUS was associated with significantly lower occurrence

56 ine and one year) were re-analyzed at a core IVUS laboratory.

57 Our preliminary serial 3D coronary IVUS data show that H+LTx attenuates cardiac allograft v

58 Patients underwent a baseline coronary IVUS, which was repeated after 2 years of amlodipine, en

59 lumen volumes were compared between coronary IVUS studies at baseline and follow-up.

60 respective of performance of second coronary IVUS.

61 ee-dimensional intravascular ultrasound (3-D IVUS) examination of the left anterior descending corona

62 -DES, the largest study of IVUS use to date, IVUS guidance was associated with a reduction in stent t

63 Three-dimensional IVUS was performed after intervention and at 9-month fol

64 Two-dimensional IVUS measurements and vessel, lumen and plaque volume we

65 provides higher resolution imaging than does IVUS, although findings from some studies suggest that i

66 nt for differences in baseline risk factors, IVUS-guidance was associated with significantly lower in

67 t to target lumen revascularization favoring IVUS-guided coronary stent implantation, it is likely th

68 ability to safely acquire co-registered FLIm-IVUS data in vivo using Dextran40 solution flushing was

69 The unique FLIm-IVUS system evaluated here has the potential to provide

70 composition was high for IVMRI but poor for IVUS.

71 The results were similar for IVUS-defined ISR (odds ratio: 0.42; 95% confidence inter

72 Sensitivity/specificity for IVUS was 67%/65% for an optimal cutoff value of 2.36 mm(

73 Macrovascular disease was evaluated from IVUS studies and assigned into one of five grades based

74 scuss the critical information obtained from IVUS and FFR in guiding treatment of patients with inter

75 at has recently been combined with grayscale IVUS in a single catheter as the first combined imaging

76 three, stratified by site) to OCT guidance, IVUS guidance, or angiography-guided stent implantation.

77 ient) were measured by a pressure guidewire; IVUS and angiographic parameters (minimum lumen area and

78 ss the correlation between virtual histology IVUS and FFR for intermediate coronary lesions.

79 However, IVUS analysis for macrovascular disease revealed mostly

80 enetration depth simultaneously, this hybrid IVUS-OCT technology opens new and safe opportunities to

81 wever, comparisons among OCT, C-IVUS, and IB-IVUS have not been done.

82 The sensitivity of IB-IVUS was 100%, 94%, and 84%, respectively.

83 The specificity of IB-IVUS was 99%, 84%, and 97%, respectively (Cohen's kappa

84 ted backscatter intravascular ultrasound (IB-IVUS), and conventional intravascular ultrasound (C-IVUS

85 This study aimed to determine if IVUS-guided stent implantation is associated with improv

86 Balloon angioplasty eliminates or improves IVUS findings and produces substantial, sustained BP red

87 hundred and three patients were included in IVUS arms.

88 ters, frequency, and severity of stenoses in IVUS-imaged and nonimaged coronary arteries were compare

89 mum interstrut angle as the only independent IVUS predictor of IH cross-sectional area (P<0.01 and P<

90 Initially, IVUS was shown to be able to characterize plaque broadly

91 We reviewed 791 pre-intervention IVUS SVG studies and identified 95 ruptured plaques in 7

92 <65 years of age underwent pre-intervention IVUS within 2 days from onset of an MI.

93 ; grayscale intravascular ultrasound (IVUS); IVUS radiofrequency tissue characterization; optical coh

94 angiography at least one year after the last IVUS exam.

95 eluting stents for diffuse coronary lesions, IVUS-guided percutaneous coronary intervention is superi

96 and only the main vessel (MV) in 15 lesions; IVUS analysis included five distinct locations: MV proxi

97 seline and follow-up at 16.2 +/- 7.4 months) IVUS findings in 50 nonintervened SVG segments in 44 pat

98 nsplant recipients who underwent one or more IVUS examinations and coronary angiography at least one

99 A motorized IVUS pullback was used to assess coronary atheroma burde

100 onic stable angina patients with multivessel IVUS imaging.

101 gher inflation pressures were used in 74% of IVUS-guided cases.

102 The ability of IVUS to detect vulnerable plaques before rupture is curr

103 coherence tomography, the light analogue of IVUS; and near-infrared spectroscopy that detects lipid

104 troduces a challenge to standard analyses of IVUS outcomes relying on constant stent diameters over t

105 Recent advances in new applications of IVUS, such as integrated backscatter, wavelet analysis,

106 The benefits of IVUS were especially evident in patients with acute coro

107 , the safety, efficacy, and effectiveness of IVUS should be taken into account when considering the g

108 We studied the impact of IVUS guidance on outcome in patients undergoing unprotec

109 In addition, the importance of IVUS and FFR in the management of patients with serial s

110 Although multiple measures of IVUS disease burden were worse in subjects with diabetes

111 rent (p = 0.07), regardless of the number of IVUS exams and duration of follow-up.

112 In ADAPT-DES, the largest study of IVUS use to date, IVUS guidance was associated with a re

113 ted in similar minimum stent area to that of IVUS-guided PCI.

114 The utility of IVUS MLA as an alternative to FFR to guide intervention

115 The utility of IVUS to assure adequate stent expansion may be more impo

116 However, the cutoff values of IVUS parameters at which to predict a fractional flow re

117 On IVUS, the minimum lumen area of B1 decreased from 5.23 +

118 On IVUS, various endoluminal defects (eccentric ridges; flu

119 nificant increases in plaque burden based on IVUS analyses.

120 e present in the clinical characteristics or IVUS parameters between the control and TAXUS groups.

121 In 340 propensity score-matched pairs, IVUS was also associated with significantly lower occurr

122 y multivessel (2.1 +/- 0.7 arteries/patient) IVUS examination 1.0 +/- 0.5 month and 12.0 +/- 1.0 mont

123 Of 2468 patients, IVUS guidance was used in 621 (25.2%).

124 Postintervention IVUS did not identify a cause in 22% and did identify at

125 Postintervention IVUS was performed in both branches in 25 lesions and on

126 with extensive calcification that precluded IVUS interpretation.

127 on of atherosclerosis for all 3 prespecified IVUS measures of disease burden.

128 The primary prespecified IVUS end point was the in-stent percent net volume obstr

129 The primary IVUS efficacy parameter, PAV, did not differ between par

130 Recent IVUS studies have suggested that patients presenting wit

131 We used a novel "regional" IVUS analysis to assess the mechanism of LSM.

132 Disease progression was measured by repeat IVUS examination after at least 72 weeks of treatment.

133 Repeated IVUS examinations following heart transplantation do not

134 ent atheroma volume (PAV), the most rigorous IVUS measure of disease progression and regression.

135 orted clinical outcomes and compared routine IVUS-guided stent implantation with an angiography-guide

136 However, routine IVUS guidance of coronary stent implantation is not supp

137 At a mean of 15 months, routine IVUS-guided percutaneous coronary intervention was assoc

138 The diagnostic accuracy of gray-scale IVUS to identify thin-capped fibroatheromata was poor fo

139 atory analysis, and compared with gray-scale IVUS.

140 The secondary IVUS efficacy parameter, TAV, did not differ between par

141 Serial IVUS is the most accurate method for early detection and

142 Serial IVUS studies reveal details of the pattern of vascular r

143 24 months, 349 patients had evaluable serial IVUS examinations.

144 There are no serial IVUS studies of disease progression or luminal compromis

145 tients in 6 clinical trials that used serial IVUS.

146 of the results in patients with simultaneous IVUS and OCT imaging revealed no significant differences

147 In this SIRIUS IVUS substudy, SES reduced both biologic variability and

148 The minimum lumen site had a smaller IVUS lumen area at follow-up (2.7+/-0.9 versus 6.2+/-1.9

149 biochemical information that can supplement IVUS data for a comprehensive assessment of plaques path

150 iency (AUC: 0.77; 95% CI: 0.60 to 0.89) than IVUS (AUC: 0.63; 95% CI: 0.46 to 0.78) to identify funct

151 ial or future cardiovascular event risk that IVUS can serve as an efficient surrogate for clinical ev

152 The IVUS data demonstrated a numeric trend toward regression

153 The IVUS end point was change in percent atheroma volume.

154 The IVUS features of ruptured plaques included positive remo

155 The IVUS group was younger (median age, 70 versus 75 years)

156 The IVUS images were reviewed for the presence of ISA.

157 The IVUS mid-left anterior descending (LAD) luminal area was

158 The IVUS substudy showed a trend toward less progression of

159 The IVUS tapes (at baseline and one year) were re-analyzed a

160 The IVUS-defined rapid progression correlated highly with fu

161 The IVUS-detected ruptured plaques had angiographically comp

162 nderwent final OCT imaging (operators in the IVUS and angiography groups were masked to the OCT image

163 140 [34%] in the OCT group, 135 [33%] in the IVUS group, and 140 [34%] in the angiography group).

164 nts in the OCT group, one (1%) of 146 in the IVUS group, and one (1%) of 146 in the angiography group

165 djusted primary outcome trended lower in the IVUS-guided group versus the angiography-guided (6.9% vs

166 99; P=0.04) also appeared to be lower in the IVUS-guided group.

167 l assumptions, and the interpretation of the IVUS measurements that the answer cannot be taken for gr

168 ed (16 patients) or reduced (4 patients) the IVUS findings and lowered systolic BP in all (mean reduc

169 ; findings must be put into context with the IVUS findings in bare metal stents.

170 Therefore, IVUS findings in low- and high-dose patients were combin

171 egative clinical events associated with this IVUS finding at 12-month clinical follow-up; however, ca

172 450 patients (158 [35%] to OCT, 146 [32%] to IVUS, and 146 [32%] to angiography), with 415 final OCT

173 dices measured by MDCT correlated closely to IVUS (r(2) = 0.77 and r(2) = 0.82, respectively).

174 We tested non-inferiority of OCT guidance to IVUS guidance (with a non-inferiority margin of 1.0 mm(2

175 guidance, and superiority of OCT guidance to IVUS guidance, in a hierarchical manner.

176 OCT guidance was non-inferior to IVUS guidance (one-sided 97.5% lower CI -0.70 mm(2); p=0

177 Although OCT seems slightly superior to IVUS for this purpose (particularly in vessels <3 mm), i

178 red by serial intravascular ultrasonography (IVUS) imaging.

179 ce (IMR); and intravascular ultrasonography (IVUS) of the left anterior descending coronary artery, w

180 sed using intravascular coronary ultrasound (IVUS) and quantitative coronary angiography (QCA).

181 th complete serial intravascular ultrasound (IVUS) (baseline and 8-month follow-up) were analyzed.

182 s were imaged with intravascular ultrasound (IVUS) 5 and 10 min after ELIP injection (5-mg dose).

183 Intravascular ultrasound (IVUS) and cardiac MRI (CMR) were studied in patients wit

184 Intravascular ultrasound (IVUS) and fractional flow reserve index (FFR) provide an

185 relation with both intravascular ultrasound (IVUS) and histopathology for discrimination between soft

186 erosis assessed by intravascular ultrasound (IVUS) and its rate of progression in subjects treated wi

187 tegrating EIS with intravascular ultrasound (IVUS) and shear stress (ISS) provided a new strategy to

188 oncomitant OCT and intravascular ultrasound (IVUS) area measurements were performed in a subgroup of

189 dity of first-year intravascular ultrasound (IVUS) data as a surrogate marker for long-term outcome a

190 Serial intravascular ultrasound (IVUS) data from the Reversal of Atherosclerosis with Agg

191 In vivo intravascular ultrasound (IVUS) data were acquired from 14 patients and IVUS-based

192 phy and volumetric intravascular ultrasound (IVUS) evaluation of the left anterior descending artery

193 Patients underwent intravascular ultrasound (IVUS) evaluation of the target vessel during the cathete

194 impact of repeated intravascular ultrasound (IVUS) examinations on transplant coronary artery disease

195 ue volume (CPV) by intravascular ultrasound (IVUS) examinations.

196 We report intravascular ultrasound (IVUS) findings after crush-stenting of bifurcation lesio

197 , it is unknown if intravascular ultrasound (IVUS) guidance for percutaneous coronary intervention sh

198 Intravascular ultrasound (IVUS) guidance has been shown to reduce major adverse ca

199 ggest a benefit of intravascular ultrasound (IVUS) guidance in noncomplex lesions.

200 etter outcome with intravascular ultrasound (IVUS) guidance when performing unprotected left main cor

201 Intravascular ultrasound (IVUS) has become an indispensable part of all drug-eluti

202 Intravascular ultrasound (IVUS) has played an integral role in the evolution of in

203 Intravascular ultrasound (IVUS) has the ability to detect and localize plaque as w

204 rdial biopsies and intravascular ultrasound (IVUS) images of coronary arteries in 33 heart transplant

205 underwent coronary intravascular ultrasound (IVUS) imaging and were randomized to receive 300 mg of a

206 e tomography (OCT)-intravascular ultrasound (IVUS) imaging at 72 frames per second safely in vivo, i.

207 ed with volumetric intravascular ultrasound (IVUS) imaging.

208 Intravascular ultrasound (IVUS) is being used to assess the significance of a left

209 Although intravascular ultrasound (IVUS) is widely used to detect early transplant coronary

210 er the guidance of intravascular ultrasound (IVUS) or conventional angiography at a large single cent

211 High-frequency intravascular ultrasound (IVUS) revealed atherosclerotic lesions in the regions wi

212 ry angiography and intravascular ultrasound (IVUS) studies were performed annually to evaluate severi

213 rial 3-dimensional intravascular ultrasound (IVUS) studies were performed within 8 weeks (baseline; B

214 who completed the intravascular ultrasound (IVUS) substudy of the CAMELOT (Comparison of Amlodipine

215 umen area (MLA) by intravascular ultrasound (IVUS) that correlates with fractional flow reserve (FFR)

216 We used serial intravascular ultrasound (IVUS) to assess disease progression in nonintervened sap

217 s study was to use intravascular ultrasound (IVUS) to compare octogenarians versus patients <65 years

218 ent study analyzed intravascular ultrasound (IVUS) to define the changes that take place in the arter

219 nd preintervention intravascular ultrasound (IVUS) to determine the incidence and magnitude of SVG ca

220 We used intravascular ultrasound (IVUS) to evaluate recurrence after sirolimus-eluting ste

221 serial volumetric intravascular ultrasound (IVUS) to evaluate the effect of preinterventional arteri

222 serial volumetric intravascular ultrasound (IVUS) to evaluate the effects of polymer-based, paclitax

223 Prior intravascular ultrasound (IVUS) trials have demonstrated slowing or halting of ath

224 y angiography, and intravascular ultrasound (IVUS) were evaluated in subjects enrolled in a study com

225 catheter combining intravascular ultrasound (IVUS) with multispectral fluorescence lifetime imaging (

226 e gradients (TPG), intravascular ultrasound (IVUS), and angiographic parameters in predicting hyperte

227 onth angiographic, intravascular ultrasound (IVUS), and clinical follow-up were conducted.

228 onary angiography, intravascular ultrasound (IVUS), and optical coherence tomography (OCT) at differe

229 ex imaging (CFDI), intravascular ultrasound (IVUS), and renal arteriography in diagnosing renal arter

230 Intravascular ultrasound (IVUS)-attenuated plaque is characterized by absence of u

231 ressive changes in intravascular ultrasound (IVUS)-derived indexes of plaque size sufficiently predic

232 Intravascular ultrasound (IVUS)-derived lumen, outer stent/scaffold, and reference

233 lationship between intravascular ultrasound (IVUS)-derived measures of atherosclerosis and cardiovasc

234 the efficacy of an intravascular ultrasound (IVUS)-guided strategy for patients with angiographically

235 nsional volumetric intravascular ultrasound (IVUS).

236 ared with those of intravascular ultrasound (IVUS).

237 ell described with intravascular ultrasound (IVUS).

238 sis progression by intravascular ultrasound (IVUS).

239 que progression by intravascular ultrasound (IVUS).

240 CAG) alone or with intravascular ultrasound (IVUS).

241 al (3D) volumetric intravascular ultrasound (IVUS).

242 reserve; grayscale intravascular ultrasound (IVUS); IVUS radiofrequency tissue characterization; opti

243 serial qualitative intravascular ultrasound (IVUS; at stent implantation and eight-month follow-up) w

244 011, a total of 1,899 patients who underwent IVUS-guided (n = 713, 37.5%) or conventional angiography

245 Each pair of baseline and follow-up IVUS assessments was analyzed in a blinded fashion.

246 analyzed poststenting and 13-month follow-up IVUS in 186 patients (195 lesions) with acute myocardial

247 tically significantly decreased at follow-up IVUS in patients who received beta-blockers (P < 0.001)

248 age slices on postimplantation and follow-up IVUS studies of 11 malapposed stents were identified and

249 onal, post-stent implantation, and follow-up IVUS were available in 18 low-dose and 21 high-dose pati

250 At nine-month follow-up, IVUS lumen volumes were larger in the TAXUS group (123 +

251 tient-based analysis of 64-slice CCTA versus IVUS showed a mean weighted sensitivity and specificity

252 VH-IVUS plaque classification, and particularly VH-IVUS-def

253 Local observers classified 100 VH-IVUS-defined coronary plaques to determine single center

254 aps against coregistered histology in 72 (VH-IVUS) and 87 (CT) segments from 8 postmortem coronary ar

255 A VH-IVUS assessment may add important information in the eva

256 However, although VH-IVUS could identify thin-cap fibroatheromas (TCFA) with

257 We also assessed VH-IVUS and CT Plaque Maps against coregistered histology i

258 (2)], p = 0.027) areas; however, baseline VH-IVUS plaque composition did not differ between VH-TCFAs

259 However, direct comparisons between VH-IVUS and OCT are lacking and it remains unknown whether

260 Both VH-IVUS and OCT can reliably identify TCFA, although OCT ac

261 The presence of VHD-IP as assessed by VH-IVUS is associated with early recurrent rejection and wi

262 Single-center VH-IVUS inter-observer agreement was strong (kappa=0.86), b

263 Combined VH-IVUS/OCT imaging markedly improved TCFA identification.

264 ification was 63.6%, 78.1%, and 76.5% for VH-IVUS and 72.7%, 79.8%, and 79.0% for OCT.

265 Differences in VH-IVUS plaque definitions introduce further variability be

266 accuracy of local versus core-laboratory VH-IVUS plaque classification and effects of different plaq

267 These factors reduce the use of VH-IVUS plaque classification to guide intervention in a "l

268 On VH-IVUS, plaque (10.91+/-4.82 versus 8.42+/-4.57 mm(2); P=0

269 S plaque classification, and particularly VH-IVUS-defined thin-capped fibroatheromata identification,

270 to pathological intimal thickening (PIT), VH-IVUS-derived thin-capped fibroatheroma (VH-TCFA), thick-

271 ferent plaque definitions further reduced VH-IVUS-defined thin-capped fibroatheromata numbers by 44%.

272 Based on the VH-IVUS plaque characteristics, coronary allograft plaque w

273 que components with a similar accuracy to VH-IVUS ex vivo.

274 rtual-histology intravascular ultrasound (VH-IVUS) and optical coherence tomography (OCT) can assess

275 rtual histology intravascular ultrasound (VH-IVUS) can identify plaques at high risk of rupture, such

276 rtual histology intravascular ultrasound (VH-IVUS) imaging to assess the presence and predictors of v

277 rtual histology intravascular ultrasound (VH-IVUS) in 108 plaques from 57 patients.

278 rtual histology intravascular ultrasound (VH-IVUS) to investigate the natural history of coronary art

279 coronary allograft vasculopathy underwent VH-IVUS examination of the left anterior descending coronar

280 serial (baseline and 12-month follow-up) VH-IVUS studies and examined 216 nonculprit lesions (plaque

281 gy and compared with coregistered ex vivo VH-IVUS and OCT.

282 ability was determined by comparison with VH-IVUS core-laboratory analysis, and compared with gray-sc

283 Plaque Maps correlated significantly with VH-IVUS-determined plaque component volumes (necrotic core:

284 roma (80% versus 79%) was comparable with VH-IVUS.

285 rt of a formal substudy, complete volumetric IVUS data were available in 170 patients, including 88 T

286 (1%) of 146 in the angiography group (OCT vs IVUS p=0.37; OCT vs angiography p=0.37).

287 Whether IVUS guidance is associated with improved clinical outco

288 th OCT guidance, 5.89 mm(2) (4.67-7.80) with IVUS guidance, and 5.49 mm(2) (4.39-6.59) with angiograp

289 similar to or better than that achieved with IVUS guidance and better than that achieved with angiogr

290 trials that employed serial assessments with IVUS.

291 directed antibodies are also associated with IVUS documented vasculopathy (P<0.002).

292 d plaque volume per segment as compared with IVUS (24+/-35 mm3 versus 43+/-60 mm3, P<0.001).

293 Results were compared with IVUS in a blinded fashion.

294 FFR correlates with IVUS findings and is abnormal in a significant proportio

295 ector row MDCTA show a good correlation with IVUS.

296 port the use of atherosclerosis imaging with IVUS in the evaluation of novel antiatherosclerotic ther

297 when performing unprotected LMCA PCI without IVUS guidance.

298 0 and December 2012 with baseline and 1-year IVUS were included.

299 First-year IVUS results and subsequent five-year clinical follow-up

300 gle-center studies have suggested first-year IVUS results might be a surrogate marker for long-term o